The Drug Formulary Commission (“Commission”) is established by Massachusetts General Law Chapter 17, Section 13 and by regulation at
105 CMR 720.050 . The Commission has been in existence for a number of years and its members are appointed by the Governor. Historically, the Commission’s main focus has been to develop a list of those drug products on the Massachusetts List of Interchangeable Drugs that are safely interchangeable (i.e., equivalent to each other in all significant respects).
In 2014, Chapter 258 of the Acts of 2014 was passed. This new law mandated the Commission to expand its responsibilities and tasked it with preparing a drug formulary of substitutions for Schedule II or III opiates that the Commission has determined have a heightened level of public health risk due to the drugs’ potential for abuse and misuse. Opioid abuse is a public health epidemic and this significant undertaking by the Commission will serve as an important tool aimed at preventing and treating addiction.
A second public hearing on amendments to 105 CMR 720.000 – List of Interchangeable Drug Products was held on Friday, July 7, 2017.
The deadline to submit new testimony was 5:00 p.m. on Tuesday, July 11, 2017. All testimony from the January 2017 and July 2017 hearings is under consideration.
- July 7, 2017 Public Hearing Notice
- January 2017 Public Comments
- Proposed Amendments to 105 CMR 720.000
The Drug Formulary Commission meeting scheduled for Thursday, September 21, 2017 has been cancelled.
Information regarding upcoming meetings will be available soon.
Additional Future Meetings (subject to change)
All meetings of the Drug Formulary Commission will be held at the Massachusetts Department of Public Health, Henry I. Bowditch Public Health Council Room, 2nd Floor, 250 Washington Street, Boston MA (unless otherwise noted).